According to a decree signed by the President of Uzbekistan on March 5, additional measures have been established to stimulate production and improve scientific research processes in the pharmaceutical sector. These measures include the provision of tax and customs incentives for pharmaceutical enterprises, as well as financial support from various funds.
Specifically, manufacturers who begin production of original medicines within 1 year after the expiration of their patent will be reimbursed for 50% of technology transfer costs (but not more than 50,000 US dollars) or 50% of scientific research costs (but not more than 100,000 US dollars) from the funds of the Pharmaceutical Network Support and Development Fund. These incentives are aimed at boosting local production and encouraging innovation.
Starting from June 1, 2026, business entities that implement new investment projects focused on producing high-tech medicines and launch industrial-scale production within 3 years will have their interest expenses on loans attracted within the project compensated for a period of 2 years from the funds of the Pharmaceutical Network Support and Development Fund. This measure helps attract investments and develop the pharmaceutical industry.
By September 1, 2026, enterprises producing pharmaceutical and other products that have a certificate for locally manufactured goods, regardless of the level of localization, will be allowed to sell these products on the electronic cooperation portal, manufacturers' ecosystem, local auction trades, and in the "national store." This expands sales opportunities for local products.
Business entities implementing investment projects aimed at producing pharmaceutical products, cultivating medicinal plants, or processing them will be exempt from land tax for Z years from the start date of the investment project until 2040, from profit tax for 3 years from the date the project is put into operation, and from property tax on built real estate objects. These incentives apply only if the share of income from the sale of produced pharmaceutical products or from the cultivation or processing of medicinal plants constitutes at least 60% of the taxpayer's total income volume.
Starting from April 1, 2026, enterprises producing biologically active additives and cosmetic products will not be subject to customs duties when importing equipment, its components, and spare parts that are not manufactured in Uzbekistan. This measure reduces costs for imported equipment and aids in the development of local production.
Source: www.gazeta.uz